Towards a new concept in drug delivery
Lifesome therapeutics offers a reliable and highly versatile
lipid technology opening a whole new world of applications
in personalized medicine.
The revolution and evolution in nanotechnology carriers for drug delivery.
We build unique drug delivery nanosystems assembled from therapeutic agents that maximize treatments outcomes.
High efficacy
Non-toxic
Highly versatile
Therapeutic properties
Therapeutic nanocarriers for helping researchers and pharmaceutical investigation.
Our new lipid technology enables the development of advanced novel therapies and pharma products.
Current research areas
Ohmline for cancer treatments
Among dozens of compounds targeting membrane proteins involved in cancer, Ohmline by Lifesome stands out. It uniquely combines therapeutic agent and nanocarrier properties, revealing the potential synergistic effects of this exclusive lipid compound.
Ohmline as antimicrobial agent
Antibiotic resistance is a main concern among nowadays letal diseases. Lifesome nanotehcnology with intrinsic antimicrobial activity can be used to repurpose antibiotics, tackle antibiotic resistance and improve their therapeutic activity.
Supports and Partners
The project “Development of Novel Lipid Nanoparticles with Antitumor and Antimetastatic Functions”, carried out throughout 2024 and 2025 within the framework of the «Ayudas para el desarrollo de nuevas empresas innovadoras de base tecnológica, Start-up 2023, Línea 1: Nuevas pymes innovadoras de base tecnológica de hasta 1 año de antigüedad», has been funded by the Comunidad de Madrid and the European Regional Development Fund (ERDF).
The main objective of the project is to explore the therapeutic applications of lipid-based nanoparticles for the treatment and prevention of melanoma and other skin cancers.
To achieve this, the project has involved the management and planning of R&D activities focused on the development of different lipid-based formulations and their evaluation through in vitro and in vivo experiments. The promising results obtained in skin cancer have enabled us to expand the development of new applications targeting various solid and hematological tumors.
We believe in the power of partnerships that are based on mutual trust and recognize the added value of combining experience, know-how and competences.